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The 2014 epidemic of Ebola virus dis-
ease (EVD) in several West African coun-
tries has mortality rates of up to 70%,
as reported by WHO. The exponential
increase in the number of infections and
deaths, coupled with the absence of spe-
cific preventive and therapeutic strategies,
represents one of the biggest global health
challenges of this millenium. Insights in
the pathophysiology and treatment of EVD
are thus urgently needed. In this paper,
we postulate that EVD has the character-
istics of hemophagocytic lymphohistiocy-
tosis (HLH) syndrome (syn., macrophage
activation syndrome). The identification
of HLH as part of severe EVD, however,
brings the possibility for a pathophysiolog-
ically targeted approach of therapy; spe-
cial promise is represented by cytokine-
directed therapy in the form of recom-
binant interleukin-1 receptor antagonist
(anakinra). Treatment with anakinra has
the advantage to interrupt the deleterious
IL-1-mediated hyperinflammatory loop in
macrophage activation syndrome, and it
has been shown to be associated with
remarkable effectiveness and an excellent
safety record.
CLINICAL SYNDROME
After an incubation period of 2–21 days,
the symptoms of EVD present that resem-
ble flu, including chills, fever, myalgia, and
general malaise. As the disease progresses,
abdominal complaints such as anorexia,
nausea, vomiting, abdominal pain, diar-
rhea, as well lethargy, headache, and
hypotension develop. Also bleeding may
develop in 30–50% of patients, however,
the severity varies. Bleeding is not per se
associated with fatal outcome. In severe and
fatal forms, death occurs between 6 and
16 days after symptoms appeared because
of shock, seizures, severe metabolic com-
plications, and bleeding. In lethal cases, a
high blood viral load is seen, accompanied
by a significant increment in blood neu-
trophils, drop in numbers of lymphocytes
and platelets, and coagulation abnormali-
ties (1).
Laboratory findings include initially
leukopenia (which may drop to 1000
cells/µL) with lymphopenia, while neu-
trophilia develops thereafter with a left
shift with atypical lymphocytes, throm-
bocytopenia (50000–100000 cells/µL), ele-
vated liver functions with higher aspar-
tate aminotransferase levels compared to
alanine aminotransferase, hyperproteine-
mia, and proteinuria. Diffuse intravascular
coagulopathy may be present because of
prolonged prothrombin and partial throm-
boplastin times and the presence of fibrin
split products. When a secondary bacter-
ial infection eventually may develop, ele-
vated numbers of white blood cells are
documented. In fatal cases, a high blood
viral load is seen, accompanied by a signif-
icant rise in blood neutrophil count, a pro-
gressive drop in lymphocyte and platelet
counts, and diffuse coagulation abnormal-
ities (1).
PATHOGENESIS OF EBOLA VIRUS
DISEASES
Little is known about the pathology and
pathogenesis of EVD in humans. Ebola
virus has a broad cell tropism infect-
ing not only immune cells like mono-
cytes, macrophages, and dendritic cells
but also various epithelial cells as well as
endothelial cells, fibroblasts, hepatocytes,
and adrenal cortical cells. Data from exper-
imentally infected non-human primates
using Zaire Ebola virus suggest that mono-
cytes, macrophages, and dendritic cells
are probably preferably infected at first,
whereby these cells subsequently play a sig-
nificant role to disseminate the virus by
spreading it from the side of infection to
draining lymph nodes and then to liver
and spleen. The tropism of Ebola virus for
lymphoid tissue, the liver, and the adrenal
gland is important for the pathogenesis as
adreno-cortical dysfunction by Ebola virus
infection could contribute to the develop-
ment of shock that characterizes the late
stage of disease.
Studies in non-human primates and
lethal human EVD show significant lym-
phocyte reduction and necrosis in spleen,
thymus, and lymph nodes, although a sig-
nificant cellular inflammatory reaction is
lacking in these or other infected tissues.
The apoptosis that is generally noticed
in lymphocytes in infected humans and
in non-human primates may clarify the
increasing peripheral lymphopenia and tis-
sue lymphoid depletion at post-mortem
studies. T-lymphocyte and natural-killer
cell populations are mostly reduced in
macaques infected with Zaire Ebola virus
(2) while human studies indicate that the
number of NK cells generally decrease
while fatal cases are characterized by
especially reduced T-cells counts (3). In
addition, blood d-dimer levels can be
found in EVD, but are fourfold higher
in non-survivors, indicating disseminated
intravascular coagulation (DIC) as an
important component of severe EVD (4).
HOST IMMUNE RESPONSE DURING
EVD
A substantial release of pro-inflammatory
mediators and vasoactive elements has
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been shown in patients with severe EVD,
contributing to inflammation and coagu-
lation (5). In addition, an ineffective host
response causes a high viral load that con-
tributes to a pro-inflammatory state. The
release of pro-inflammatory cytokines by
monocytes and macrophages is deleterious
by causing endothelial leakage, hypoten-
sion, DIC, and multiorgan failure, hence
a syndrome that closely resembles sep-
tic shock. A recent study using 86 sam-
ples from the 2000–2001 Uganda outbreak
correlated inflammatory biomarkers with
clinical outcome, and found that death was
associated with elevated concentrations of
cytokines (IL-1α, IL-1RA, IL-6, MCP-1,
MCSF, MIP-1α) and elevated d-dimer lev-
els, as was found by others. Interestingly,
this study also found elevated thrombo-
modulin and ferritin concentrations, being
associated with hemorrhage and death (6).
Host immune responses have also
been studied in non-human primates,
the current gold standard experimen-
tal model of EVD. Strongly up-regulated
cytokines/chemokines, including IL-1α,
IL-1Ra, IL-6, MCP-1, MIP-1α, IL-15, and
IL-18 were reported in experimentally
infected macaques (7). Another striking
finding was that, although initially fibrino-
gen levels increase, in the terminal stages
of the infection plasma fibrinogen levels
were found to decrease rapidly. In humans,
plasma fibrinogen levels are generally low,
as diffuse intravascular coagulation is very
common (1).
HEMOPHAGOCYTIC
LYMPHOHISTIOCYTOSIS
Hemophagocytic lymphohistiocytosis
(also called macrophage activation syn-
drome) is an often fatal syndrome of
exaggerated but ineffective inflamma-
tory response, characterized by excessive
macrophage and T-cell activation and an
impaired capacity of NK cells and cyto-
toxic T cells to kill target cells (8). There
are eight diagnostic criteria including fever,
splenomegaly, cytopenias affecting at least
two of the three lineages in the periph-
eral blood, hyperferritinemia >5000µg/L,
hypertriglyceridemia or hypofibrinogen-
emia, hemophagocytosis in the bone
marrow, spleen, or lymph nodes, low or
absent NK cell activity determined by 51-
Cr release assay, and high levels of sCD25
(soluble interleukin-2 receptor). Five of
these eight diagnostic criteria are required
for diagnosis. Both familial (genetic due
to mutations in the perforin pathway)
(9) and acquired (reactive) forms of the
syndrome are recognized, the latter being
triggered by infectious, autoimmune, or
neoplastic conditions. Most cases of virus-
induced HLH are due to viruses of the
herpes family, although a number of
other viruses, including parvovirus B19,
measles, mumps, influenza, enterovirus,
and dengue have also been reported in
association with HLH. The key event in
HLH is a “cytokine storm” resulting in
pancytopenia and hypertriglyceridemia. In
addition, the macrophage activation leads
to sustained and uncontrolled macrophage
and histiocyte infiltration, resulting in
hepatosplenomegaly, release of plasmino-
gen activator promoting hypofibrinogene-
mia, up-regulation of hemoxygenase, and
increase in ferritin levels.
HYPOTHESIS: SEVERE EVD IS
CHARACTERIZED BY OVERWHELMING
MACROPHAGE ACTIVATION
SYNDROME
Based on the clinical and pathophysiolog-
ical characteristics of EVD, we hypoth-
esize that infection with Ebola virus is
associated with overwhelming macrophage
activation in the setting of a secondary
HLH. Strong arguments for this hypoth-
esis are the presence of fever, cytopenia,
hypofibrinogenemia, low NK cells, and
strikingly elevated ferritin levels, which are
also commonly found in EVD, especially
in the patients with a fatal outcome. In
addition, less perforin mRNA expression
was found in peripheral blood mononu-
clear cells of patients with fatal Ebola
infection compared to those that survived
(10), while animal studies indicated that
CD8-mediated protection against Ebola is
perforin-dependent (11).
Cytopenias are key laboratory mark-
ers of HLH and are attributed to
severe cytokine-mediated inflammation
(12). Patients with Ebola infection are often
leucopenic at presentation, with abnor-
mal low numbers of lymphocytes and
an increased percentage of granulocytes
(13). Interestingly, total leukocyte numbers
abnormally increase with a rise in imma-
ture granulocytes and atypical lympho-
cytes while the disease develops: this may
mirror hyperactivation of bone marrow by
cytokines of the IL-1 family that have been
proposed to mediate the systemic hyperin-
flammatory reaction in HLH (14). Throm-
bocytopenia is a constant feature of EVD,
with bone-marrow studies suggesting that
thrombocytopenia is not due to reduced
platelet production but rather to diffuse
intravascular coagulation, as has also been
reported in 40–90% of HLH cases (12).
A striking recent finding is the hyperfer-
ritinemia in Ebola patients, with mean val-
ues around 10,000µg/L in non-survivors,
and 2,500µg/L in non-fatal cases at day 6–
10 after symptom onset. Although hyper-
ferritinemia can be encountered in infec-
tions, autoimmune diseases, and several
rare syndromes, such very high ferritin
concentrations of more than 10,000µg/L
indicate HLH with a sensitivity of 90% and
specificity of 96% (ref).
There are also characteristics of EVD
that might argue against a classical HLH
syndrome. Histiocytic infiltrates of various
organs, including liver and spleen, are to be
expected in HLH; however, a recent review
of human pathology studies indicates that
only minimal inflammation is observed in
infected tissue and organs in fatal cases,
despite high viral loads and necrotic lesions
(5). However, Kupffer cell hyperplasia is
seen in Ebola infections, similar to HLH
(15). Furthermore, no hemophagocytosis
has been reported to date in EVD, although
very few (if any) studies have been done
in this respect. Moreover, the hemophago-
cytic activity might not occur at all stages
of the disease (12) and therefore does not
have to be present to diagnose HLH (8).
CONCLUSION AND FUTURE
PERSPECTIVES
In conclusion, the clinical manifestations
and pathophysiology of severe EVD lead
us to propose that HLH characterized by
overwhelming macrophage activation is a
key event in the pathogenesis of the Ebola
infection.
It has been proposed that sepsis, sys-
temic inflammatory response syndrome,
multiple organ dysfunction syndrome, and
HLH form a disease continuum that share
a common mechanism: systemic immune
dysregulation triggered by a specific exter-
nal agent (12). We think that these con-
ditions occur in Ebola virus infection.
The metabolic and immune imbalance
during EVD requires both optimal support
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measures and the removal of the trigger
(infection) that stimulate inflammation.
Unfortunately, the latter is not feasible,
because no antiviral medication has been
of proven efficacy in EVD.
The identification of HLH as part of
severe EVD, however, brings the pos-
sibility for a pathophysiologically tar-
geted approach of therapy, using the
arsenal of immunomodulatory medica-
tion known to be successful in HLH.
While plasma exchange, corticosteroids,
and even immunosuppressive therapy have
been proposed for treatment of HLH, spe-
cial promise is represented by cytokine-
directed therapy in the form of recom-
binant interleukin-1 receptor antagonist
(anakinra). Treatment with anakinra has
the advantage to interrupt the deleterious
IL-1-mediated hyperinflammatory loop in
macrophage activation syndrome, and it
has been shown to be associated with
remarkable effectiveness (16–20). More-
over, the excellent safety record of anakinra
argues for its compassionate use in patients
with severe EVD in humans.
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